Patiromer

Background

A potassium binding polymer that unlike Kayexylate has not been reported to increase the risk of intestinal necrosis.

Administration

• Type: oral powder for suspension

• Dosage Forms:
  • 8.4g/packet
  • 16.8g/packet
  • 25.2g/packet
• Routes of Administration:
• Common Trade Names:

Adult Dosing

• 8.4 g PO qDay
• May increase or decrease dose as necessary (increments of 8.4 g) not to exceed 25.2 g qDay

Pediatric Dosing

Safety not established

Special Populations

Renal Dosing

• Adult: no adjustments
• Pediatric: not approved

Hepatic Dosing

• Adult: no adjustment
• Pediatric: not approved

Contraindications

• Allergy to class/drug

Adverse Reactions

Serious

• Excessive doses > 50g/d can cause profound hypokalemia

Common

• Constipation (7.2%)
• Hypomagnesemia (5.3%)
• Diarrhea (4.8%)
• Nausea (2.3%)
• Abdominal discomfort (2%)
• Flatulence (2%)

Pharmacology

• Half-life:
• Metabolism: non-absorbed polymer
• Excretion: Fecal

Mechanism of Action

• Binds and removes (via sorbitol induced bowel movements) potassium from the GI tract==Comments==

See Also

• Kayexylate